America is more than capable of saving the day

Continued uphill battle in Europe

Idefirix superiority confirmed

Investor AB: 1 director

A director at Investor AB bought 1,672 shares at 298.400SEK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

A double-edged sword in recovery

Waiting for an inflection point

Avanza Bank Holding AB: 2 directors

Two Directors at Avanza Bank Holding AB bought 784 shares at between 327.400SEK and 339.000SEK. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...

New CEO, new execution

Q1: New CEO with track record

Pipeline the main trigger in 2025

Patience is a virtue

Q4: Year-end sales bump

A closer look at GBS and NiceR

Solid GBS IGOS efficacy analysis

Initiates Ph 2 in Crigler-Najjar syndrome

Keeping the momentum going

Q3: Strong sales offset by heavy provision

Takeaways from NiceR call

NiceR (5487) is nicer than Imlifidase

Stable quarter but time to grow in H2

EU adj. sales development neutral. Cash burn to improve in H2 after one-offs in Q2. Revising our model: BUY, TP SEK 88 (98).